Our Approach

Ardelyx develops:

  • Innovative, minimally-systemic, small molecule and polymeric therapeutics that work exclusively in the GI tract to treat GI and cardio-renal diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas



Reduce systemic uptake, minimize side effects.

Program Indication Research Phase
1
Phase 2 Phase
3
Status
2a 2b 2a 2b
Tenapanor(NHE3 Inhibitor) IBS-C *  *  *  *  *  *  *  *  *  Results of Two
Phase 3 Trials
Expected 2017
ESRD Hyperphosphatemia *  *  *  *  *  *  *  *  *  Results of First
Registration Trial
Expected 1Q 2017
RDX227675(Potassium Binder) Hyperkalemia *  *  *  *  *  *  *  *  *  Phase 3 Trial
Initiation
4Q 2016
RDX98940(TGR5 Agonist) Various GI Indications *  *  *  *  *  *  *  *  *  IND Filing
Planned for
4Q 2016
RDX013
(Potassium Secretagogue)
Hyperkalemia *  *  *  *  *  *  *  *  *  Research
RDX011
RDX023
RDX024
Various GI and Cardio-Renal Indications *  *  *  *  *  *  *  *  *  Research